ArcheOptix Biomedical

ArcheOptix operates in the specialized segment of portable neurodiagnostics, targeting traumatic brain injury assessment outside conventional CT-equipped environments. Its stated differentiation is the combination of near-infrared optical imaging, portability, non-invasive operation, and an intended ability to identify acute subdural and epidural hematomas without ionizing radiation. The company positions NIRD® for emergency departments, rural and underserved communities, sports, military use, and other settings where patient transport or access to full-size imaging can delay triage. The product’s reported 8.5-pound design and minimal preparation requirements support a point-of-care use case distinct from fixed hospital imaging infrastructure. Its 11 granted patents, six registered trademarks, and stated Health Canada approval provide evidence of regulatory and intellectual-property progress, but commercialization scale, reimbursement adoption, and clinical deployment remain unclear.

ArcheOptix’s trajectory reflects a long-cycle medical-device development model rather than a high-velocity software growth pattern. Founded in 2016, the company has developed a focused product platform around NIRD®, a portable near-infrared brain-imaging device designed for traumatic brain injury assessment. The principal inflection point visible in the profile is the transition from technology development toward commercialization, supported by the company’s statement that the technology is Health Canada approved. Its intellectual-property position—11 granted patents and six registered trademarks—also indicates continued investment in protecting the underlying device and brand. Employee information indicates a very small organization of approximately one to ten people. Growth should therefore be evaluated primarily through regulatory adoption, clinical evidence, and deployment partnerships.